Key Highlights

₹200,108 Mn

Total Revenue From Operations

₹39,307 Mn

EBITDA

1,420,000+

Patients Reached Through Patient Education Programs

78,000+

HCPs Participated in Doctor Education Programs

21% YoY

Reduction in Scope 1 and Scope 2 Emissions in FY24

R&D

866

Active Patent Applications up to March 2024

442

ANDAs and NDAs filled with U.S. FDA up to March 2024

Rankings

3rd

in the U.S. (by prescriptions)

7th

in Indian Pharma Market

11th

Largest Generics Company Globally

Products

25+

Robust Pipeline of injectables for FY25

15+

Robust Pipeline of Respiratory Products for FY25

27 Bn+

Formulation Units Sold Globally (IQVIA MAT Mar 24 Standard Units)

Our Capitals

Financial Capital

Manufactured Capital

Intellectual Capital

Human Capital

Natural Capital

Social and
Relationship Capital

Download Reports

INTEGRATED REPORT
2023 - 2024

Download

Leadership Messages